In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

AUTOR(ES)

García-Rodríguez, J A

RESUMO

The in vitro activities of amoxicillin, cefuroxime, ceftetrame, cefetamet, cefixime, tigemonam, erythromycin, roxithromycin, and dirithromycin against 30 clinical isolates of Campylobacter pylori were determined by an agar dilution technique. Roxithromycin and amoxicillin (MICs for 90% of isolates tested, 0.01 and 0.06 micrograms/ml, respectively) were the most active antibiotics tested, but all strains were susceptible to all antimicrobial agents tested.

Documentos Relacionados

• In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases.
• In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.
• In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.
• Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.
• Paradoxical antibacterial activities of beta-lactams against Proteus vulgaris: mechanism of the paradoxical effect.